Navigation Links
New Guidelines Issued on Hormone Receptor Testing for Breast Cancer
Date:4/20/2010

Up to 20% of current results may be inaccurate, study says

TUESDAY, April 20 (HealthDay News) -- The American Society of Clinical Oncology and the College of American Pathologists have issued new guidelines to improve the accuracy of the testing of estrogen and progesterone receptors in breast cancer patients.

The growth of as many as two-thirds of breast cancers are thought to be affected by the action of the estrogen-receptor pathway.

Estrogen (ER) and progesterone receptor (PgR) testing allows doctors to determine whether a patient's breast cancer fits into that group. In that case, the patient may be eligible to be treated with so-called endrocrine therapies -- including the drug tamoxifen -- that can improve survival.

But there's a problem: Worldwide, as many as 10 percent to 20 percent of these screens, known as immunohistochemistry tests, may be wrong.

"There is clearly a need to accurately identify breast cancer subtypes as ER- and/or PgR-positive to help us identify those patients most likely to benefit from endocrine therapy and minimize the risk of potentially denying effective and lifesaving therapy to patients incorrectly labeled as having ER/PgR-negative invasive disease, while allowing patients with true ER/PgR-negative disease to be considered for other therapies," Dr. Antonio C. Wolff, co-chair of a joint panel on hormone receptor testing in breast cancer and a professor of oncology at Johns Hopkins Kimmel Cancer Center in Baltimore, said in a news release.

Among a long list of recommendations, the guidelines encourage regular testing in newly diagnosed invasive breast cancers, uniform testing procedures and validation of tests.

The new guidelines were published April 19 in the Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.

More information

For more on breast cancer, see the U.S. National Library of Medicine.



-- Randy Dotinga



SOURCE: American Society of Clinical Oncology, news release, April 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NICE guidelines ration affordable osteoporosis drugs
2. Sunquest Information Systems Supports New Meaningful Use Guidelines for Laboratories Transferring H1N1 Results
3. ASTRO, ACR issue IGRT, SBRT guidelines
4. Jefferson neurosurgeon helps draft new treatment guidelines for brain metastases
5. Change in mammography guidelines questioned
6. Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training
7. New Guidelines Suggest Botox for Cerebral Palsy
8. NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy
9. ASGE issues guidelines on management of antithrombotic agents for endoscopic procedures
10. New Guidelines Urge A1C Test for Diabetes Diagnosis
11. Fewer headaches on the horizon thanks to latest guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: